Pigmented villonodular synovitis therapy with MSCF-1 inhibitors

H. Thomas Temple

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Purpose of review: Giant cell tumor of tendon sheath and pigmented villonodular synovitis are synovial-based diseases that are generally treated by surgery. For aggressive and recurrent tumors, treatment alternatives are needed. This review explores a targeted therapeutic strategy. Recent findings: Imatinib, a tyrosine kinase inhibitor, blocks expression of colony stimulating factor 1 (CSF1) by a small subpopulation of tumor cells that recruit CSF1-bearing nonneoplastic cells. Limited clinical data support the efficacy and side effect profile of imatinib in stabilizing disease in most patients. Summary: Imatinib along with other such inhibitors and monoclonal antibodies to CSF1R are putative drugs that may play an important role in the treatment of these tumors.

Original languageEnglish (US)
Pages (from-to)404-408
Number of pages5
JournalCurrent opinion in oncology
Issue number4
StatePublished - Jul 1 2012


  • colony stimulating factor 1
  • imatinib
  • pigmented villonodular synovitis
  • tenosynovial giant cell tumor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Pigmented villonodular synovitis therapy with MSCF-1 inhibitors'. Together they form a unique fingerprint.

Cite this